NASDAQ:ENGN enGene Q3 2026 Earnings Report $1.88 +0.07 (+3.57%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast enGene EPS ResultsActual EPS-$0.47Consensus EPS -$0.47Beat/MissMet ExpectationsOne Year Ago EPSN/AenGene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AenGene Announcement DetailsQuarterQ3 2026Date9/8/2026TimeBefore Market OpensConference Call DateTuesday, September 8, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) enGene Earnings HeadlinesenGene Reports Third Quarter 2026 Financial Results and Provides Business UpdateSeptember 8 at 8:00 AM | businesswire.comThese Are 7 Of The Largest Hemi Engines Ever MadeSeptember 7 at 2:35 PM | msn.comU.S. Rival Just Raised the Stakes for This Quiet CompanyIran claims a new antimony discovery could represent 10 percent of known global supply. The U.S. barely produces any newly mined antimony of its own, a metal its military depends on. As Washington pours billions into securing critical supply chains, one North American company built around a historic antimony district is drawing fresh attention. Modern technology is helping it reassess what earlier miners overlooked. See how this quiet company fits into America's strategic materials story.September 8 at 1:00 AM | i2i Marketing Group, LLC (Ad)Mechanics say Toyota’s old R-series truck engine is nearly impossible to killSeptember 7 at 2:35 PM | msn.comenGene (ENGN) Projected to Release Earnings on MondaySeptember 7 at 1:26 AM | americanbankingnews.comWhy Are Some Cummins Engines Colored Red?September 6 at 11:00 PM | msn.comSee More enGene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email. Email Address About enGeneenGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.View enGene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 AI Optical Networking Stocks Positioned for the Data Center BuildoutSafety Stocks Are Not What They Used to Be: 4 Names Built for a Weaker DollarMarketBeat Week in Review – 08/31 - 09/04Why Guidewire’s Post-Earnings Plunge May Not LastPalo Alto vs. Zscaler: Which Cybersecurity Stock Looks Stronger After Earnings?Short Sellers Are Betting Against 3 AI Infrastructure Stocks—What Could Turn the Tide?Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
